Outcomes4Me
Cambridge, US · Founded 2017 · Delaware corporation · 34 employees on LinkedIn · 8 known investors
Find your way into Outcomes4Me
565 people in our graph share verified history with the Outcomes4Me team — schools, employers, funds. One of them is your warm intro.
Wesley Chanunlockedknows Maya R. Said · together at Massachusetts Institute of Technology (overlapped)
×10knows the team · via Massachusetts Institute of Technology
knows the team · via Xerox Palo Alto Research Center
Outcomes4Me is an AI-driven patient platform that integrates with NCCN clinical oncology guidelines to provide personalized cancer care guidance, treatment options, clinical trial recommendations, and genetic testing information. The platform serves cancer patients directly by offering decision support tools and health data management to improve treatment access and outcomes.
Founders & leadership
Outcomes4Me was founded in 2017 by Maya R. Said and Osama Rahma.
MR
Maya R. SaidinFounder and CEOMaya R. Said has 15 years of experience in strategy, operations, and research across academic and industry settings in the US, Europe, the Middle East, and Asia, with expertise in healthcare. She holds a Doctor of Science degree and is fluent in English, French, and Arabic.
OR
Osama RahmainFounder and Chief Medical Advisor2017–2021
Board
AJ
DF
DA
David AucklandBoard director
Investors · 8
Asset Management CompanyMenlo Park · $500K – $2M
HealthX VenturesMadison
Sierra VenturesSan Mateo · $10M
Asset Management VenturesreportedPalo Alto
Northpond Venturesreported · 3 sourcesBethesda · $100K – $5M
Also in the syndicate · 3
IRA CapitalMerstal LtdMerstal Ltd.
Funding
SEC filings, press & company announcements$37.5M disclosed across 3 of 4 rounds · 2020–2025
- $21MraisedMay 2025 · 3 sourcesSource ↗
▶$12MraisedApr 2021 · 7 investors · Other TechnologyRule 506(b)
▶$12MraisedApr 2021 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Andrea JacksonDirector
- David AucklandDirector
- Maya SaidExecutive Officer, Director
- David FleshmanDirector
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.5MraisedJan 2020 · 6 investors · Other TechnologyRule 506(b)
▶$4.5MraisedJan 2020 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- David AucklandDirector
- David FleshmanDirector
- Maya SaidExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Cancerresearchuk5727 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
American Cancer Society (ACS)5630 shared keywordsThe American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
MD Anderson Cancer Center4302 shared keywordsUT MD Anderson is a cancer research and treatment center that provides patient care, conducts research, and offers education in cancer prevention and treatment. It is part of the University of Texas System and operates as a nonprofit medical institution.
Companies competing with Outcomes4Me for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $399.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Outcomes4Me do?
- Outcomes4Me is an AI-driven patient platform that integrates with NCCN clinical oncology guidelines to provide personalized cancer care guidance, treatment options, clinical trial recommendations, and genetic testing information. The platform serves cancer patients directly by offering decision support tools and health data management to improve treatment access and outcomes.
- Who founded Outcomes4Me?
- Outcomes4Me was founded by Maya R. Said, Osama Rahma in 2017.
- Who are Outcomes4Me's investors?
- Outcomes4Me's investors include Asset Management Company, HealthX Ventures, Sierra Ventures, Asset Management Ventures, Northpond Ventures.
- How much funding has Outcomes4Me raised?
- Outcomes4Me has disclosed $37.5M raised across 3 of its 4 known rounds.
- Where is Outcomes4Me headquartered?
- Outcomes4Me is headquartered in Cambridge, US.